<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> is the most common event leading to <z:hpo ids='HP_0001297'>stroke</z:hpo> in humans </plain></SENT>
<SENT sid="1" pm="."><plain>To understand the molecular mechanisms associated with <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, we applied the technique of <z:chebi fb="2" ids="33699">mRNA</z:chebi> differential display and isolated a gene that encodes a recently discovered <z:chebi fb="7" ids="16670">peptide</z:chebi>, adrenomedullin (AM), which is a member of the calcitonin gene-related <z:chebi fb="7" ids="16670">peptide</z:chebi> (CGRP) family </plain></SENT>
<SENT sid="2" pm="."><plain>Using the rat focal <z:hpo ids='HP_0001297'>stroke</z:hpo> model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO), we determined that AM <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly increased in the ischemic cortex up to 17.4-fold at 3 h post-MCAO (P &lt; 0.05) and 21.7-fold at 6 h post-MCAO (P &lt; 0.05) and remained elevated for up to 15 days (9.6-fold increase; P &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemical studies localized AM to ischemic neuronal processes, and radioligand (125I-labeled CGRP) displacement revealed high-affinity (IC50 = 80.3 nmol) binding of AM to CGRP receptors in brain cortex </plain></SENT>
<SENT sid="4" pm="."><plain>The cerebrovascular function of AM was studied using synthetic AM microinjected onto rat pial vessels using a cranial window or applied to canine basilar arteries in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>AM, applied abluminally, produced dose-dependent relaxation of preconstricted pial vessels (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Intracerebroventricular (but not systemic) AM administration at a high dose (8 nmol), prior to and after MCAO, increased the degree of focal ischemic injury (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced expression of both AM <z:chebi fb="2" ids="33699">mRNA</z:chebi> and <z:chebi fb="7" ids="16670">peptide</z:chebi> in ischemic cortical neurons, the demonstration of the direct vasodilating effects of the <z:chebi fb="7" ids="16670">peptide</z:chebi> on cerebral vessels, and the ability of AM to exacerbate ischemic brain damage suggests that AM plays a significant role in focal ischemic brain injury </plain></SENT>
</text></document>